The collaboration will explore and establish the value of molecular image-guided procedures for the identification and diagnosis of pulmonary...
Study will advance the validation of Cellvizio® as a real-time biopsy guidance tool during robotic-assisted bronchoscopy that may reduce the...
READ THE COMPLETE PRESS RELEASE
Global 2021 sales grew +18% year-over-year to €7.7M Mauna Kea Technologies announced fourth quarter and full year 2021 sales. Total...
Corporate resources focused on highest value clinical applications Significant reduction in operating expenses implemented Cash runway now extended...
Company to focus resources on robotic assisted interventional pulmonology and molecular imaging Nicolas Bouvier, member of the Executive Committee,...
Proven diagnostic accuracy of Cellvizio allows for successful downstaging of non-mucinous lesions and prevention of unnecessary surgeries, resulting...
Mauna Kea Technologie announced third quarter and first nine months of 2021 sales results for the periods ended September 30, 2021. First...
Further validation of how Cellvizio is a complementary technology to manual and robotic-assisted bronchoscopy, potentially impacting patient...
Mauna Kea Technologies today announced first half 2021 financial results for the six months ended June 30, 2021. First Half 2021 Financial...
Mauna Kea Technologies (the “Company”), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal...
This transaction by issuance of Units allows the Company to secure its financing until the end of the third quarter of 2022 Mauna Kea...
